Back to Search
Start Over
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
- Source :
- European Heart Journal, European Heart Journal, 2021, pp.ehab551. ⟨10.1093/eurheartj/ehab551⟩, European Heart Journal, Oxford University Press (OUP): Policy B, 2021, pp.ehab551. ⟨10.1093/eurheartj/ehab551⟩, European Heart Journal 42 (2021) 47, European Heart Journal, 42(47), 4791-4806, Ginsberg, H N, Packard, C J, Chapman, M J, Borén, J, Aguilar-Salinas, C A, Averna, M, Ference, B A, Gaudet, D, Hegele, R A, Kersten, S, Lewis, G F, Lichtenstein, A H, Moulin, P, Nordestgaard, B G, Remaley, A T, Staels, B, Stroes, E S G, Taskinen, M-R, Tokgözoğlu, L S, Tybjaerg-Hansen, A, Stock, J K & Catapano, A L 2021, ' Triglyceride-rich lipoproteins and their remnants : Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society ', European Heart Journal, vol. 42, no. 47, pp. 4791-4806 . https://doi.org/10.1093/eurheartj/ehab551
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD). Key points are (i) a working definition of normo- and hypertriglyceridaemic states and their relation to risk of ASCVD, (ii) a conceptual framework for the generation of remnants due to dysregulation of TRL production, lipolysis, and remodelling, as well as clearance of remnant lipoproteins from the circulation, (iii) the pleiotropic proatherogenic actions of TRL and remnants at the arterial wall, (iv) challenges in defining, quantitating, and assessing the atherogenic properties of remnant particles, and (v) exploration of the relative atherogenicity of TRL and remnants compared to LDL. Assessment of these issues provides a foundation for evaluating approaches to effectively reduce levels of TRL and remnants by targeting either production, lipolysis, or hepatic clearance, or a combination of these mechanisms. This consensus statement updates current understanding in an integrated manner, thereby providing a platform for new therapeutic paradigms targeting TRL and their remnants, with the aim of reducing the risk of ASCVD.<br />Graphical Abstract Formation of triglyceride-rich lipoprotein remnants and their role in atherogenesis. Metabolic scheme for the generation and clearance of triglyceride-rich lipoprotein remnant particles (A). In hypertriglyceridaemia, overproduction and inefficient lipolysis of both very low-density lipoprotein and chylomicrons lead to increased remnant formation. Triglyceride-rich lipoprotein remnants contribute to the initiation and progression of atherosclerotic lesions (B). Particle retention in the subendothelial space is followed by inflammation, cholesterol deposition, and macrophage foam cell formation.
- Subjects :
- CHOLESTERYL ESTER TRANSFER
TO-MODERATE HYPERTRIGLYCERIDEMIA
Lipoprotein remnants
030204 cardiovascular system & hematology
Bioinformatics
Residual risk
Brain Ischemia
chemistry.chemical_compound
Voeding, Metabolisme en Genomica
0302 clinical medicine
Ischaemic stroke
AcademicSubjects/MED00200
Myocardial infarction
LOW-GRADE INFLAMMATION
ALL-CAUSE MORTALITY
[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism
0303 health sciences
Atherosclerotic cardiovascular disease
digestive, oral, and skin physiology
[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism
Cardiovascular disease
Metabolism and Genomics
3. Good health
Stroke
LOW-DENSITY LIPOPROTEINS
Cardiovascular Diseases
Metabolisme en Genomica
CORONARY-ARTERY-DISEASE
Nutrition, Metabolism and Genomics
Cardiology and Cardiovascular Medicine
B-CONTAINING LIPOPROTEINS
Lipoproteins
Triglyceride-rich lipoproteins
HEART-DISEASE
03 medical and health sciences
Special Article
Voeding
medicine
Humans
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Triglycerides
030304 developmental biology
Nutrition
VLAG
Triglyceride
business.industry
APO-B
medicine.disease
Atherosclerosis
Increased risk
chemistry
3121 General medicine, internal medicine and other clinical medicine
European atherosclerosis society
business
Lipoprotein
Subjects
Details
- Language :
- English
- ISSN :
- 0195668X and 15229645
- Database :
- OpenAIRE
- Journal :
- European Heart Journal, European Heart Journal, 2021, pp.ehab551. ⟨10.1093/eurheartj/ehab551⟩, European Heart Journal, Oxford University Press (OUP): Policy B, 2021, pp.ehab551. ⟨10.1093/eurheartj/ehab551⟩, European Heart Journal 42 (2021) 47, European Heart Journal, 42(47), 4791-4806, Ginsberg, H N, Packard, C J, Chapman, M J, Borén, J, Aguilar-Salinas, C A, Averna, M, Ference, B A, Gaudet, D, Hegele, R A, Kersten, S, Lewis, G F, Lichtenstein, A H, Moulin, P, Nordestgaard, B G, Remaley, A T, Staels, B, Stroes, E S G, Taskinen, M-R, Tokgözoğlu, L S, Tybjaerg-Hansen, A, Stock, J K & Catapano, A L 2021, ' Triglyceride-rich lipoproteins and their remnants : Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society ', European Heart Journal, vol. 42, no. 47, pp. 4791-4806 . https://doi.org/10.1093/eurheartj/ehab551
- Accession number :
- edsair.doi.dedup.....e78a52ae4bac2fef8e76697493cc01bd
- Full Text :
- https://doi.org/10.1093/eurheartj/ehab551⟩